At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 24 enrolled
Drug / intervention
Anastrozole 1mg +2 moredrug
Likely dose
Anastrozole 1mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Double Blinded Placebo Controlled Trial Between Anastrozole and Clomiphene to Evaluate Improvement in Hypogonadal Symptoms and Erectile Function Using ADAM, IIEF and EHS Validated Scales
In Brief
A Phase 2 clinical trial evaluating Anastrozole 1mg, Clomiphene Citrate 25mg, and 1 other intervention for Hypogonadism, Male. Completed, enrolled 24 participants.
Detailed Summary
This study evaluates anastrazole and clomiphene in the improvement in hypogonadal symptoms and erectile function. Each subject will receive Anastrazole 1 mg/day, clomiphene 25 mg/day and placebo in randomized schedule of 8 week intervals.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypogonadism, Male
Countries--
CollaboratorsLaboratory Corporation of America
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartApr 2015
Primary CompletionMar 2017
First PostedMay 2019
TodayJul 2026
First PostedMay 1, 2019
Enrollment StartApr 2, 2015
Primary CompletionMar 8, 2017
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 7.2 years ago
Interventions
Anastrozole 1mgdrug
Clomiphene Citrate 25mgdrug
Placebo - Capdrug